Purkin et al. found that dapagliflozin 10 mg daily was associated with a significant risk of UTI compared with placebo, but SGLT-2 inhibitors did not increase the risk of severe infections, such as urosepsis and pyelonephritis [56]. This evidence concerns the gene SLC5A2 and pyelonephritis.